From pathways to targets: Understanding the mechanisms behind polyglutamine disease

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Weber, Jonasz Jeremiasz ^a,b   Sowa, Anna Sergeevna ^a,b   Binder, Tina ^a,b   Hübener, Jeannette ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Rare Disease Center   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

POLYGLUTAMINE; PEPTIDE;

CELL NUCLEUS INCLUSION BODY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; HUNTINGTON CHOREA; NONHUMAN; ONSET AGE; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PROCESSING; PROTEIN REFOLDING; PROTEIN TARGETING; PROTEIN UNFOLDING; REVIEW; SPINOCEREBELLAR DEGENERATION; ANIMAL; METABOLISM; MITOCHONDRION; NERVE DEGENERATION; PATHOLOGY; PROTEINOSIS; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; MITOCHONDRIA; NERVE DEGENERATION; PEPTIDES; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEOLYSIS; SIGNAL TRANSDUCTION;

EID: 84911917291     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/701758     Document Type: Review

References (295)

1. Orr H. T., Zoghbi H. Y., Trinucleotide repeat disorders. Annual Review of Neuroscience 2007 30 575 621 10.1146/annurev.neuro.29.051605.113042 2-s2.0-34547692622
2. Havel L. S., Li S., Li X.-J., Nuclear accumulation of polyglutamine disease proteins and neuropathology. Molecular Brain 2009 2 1, article 21 10.1186/1756-6606-2-21 2-s2.0-68149134683
3. Chai Y., Koppenhafer S. L., Bonini N. M., Paulson H. L., Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. Journal of Neuroscience 1999 19 23 10338 10347 2-s2.0-0033499931
4. Marsh J. L., Walker H., Theisen H., Zhu Y.-Z., Fielder T., Purcell J., Thompson L. M., Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Human Molecular Genetics 2000 9 1 13 25 10.1093/hmg/9.1.13 2-s2.0-0034110465
5. Duennwald M. L., Jagadish S., Muchowski P. J., Lindquist S., Flanking sequences profoundly after polyglutamine toxicity in yeast. Proceedings of the National Academy of Sciences of the United States of America 2006 103 29 11045 11050 10.1073/pnas.0604547103 2-s2.0-33746635502
6. Cohen-Carmon D., Meshorer E., Polyglutamine (polyQ) disorders: the chromatin connection. Nucleus 2012 3 5 433 441 2-s2.0-84874153820
7. Schon E. A., Manfredi G., Neuronal degeneration and mitochondrial dysfunction. Journal of Clinical Investigation 2003 111 3 303 312 10.1172/JCI200317741 2-s2.0-0037314215
8. Ikeda H., Yamaguchi M., Sugai S., Aze Y., Narumiya S., Kakizuka A., Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nature Genetics 1996 13 2 198 202 2-s2.0-0030058208
9. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S. W., Bates G. P., Exon I of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996 87 3 493 506 10.1016/S0092-8674(00)81369-0 2-s2.0-16044373842
10. Wellington C. L., Hayden M. R., Of molecular interactions, mice and mechanisms: new insights into Huntington's disease. Current Opinion in Neurology 1997 10 4 291 298 10.1097/00019052-199708000-00003 2-s2.0-0030791305
11. Klement I. A., Skinner P. J., Kaytor M. D., Yi H., Hersch S. M., Clark H. B., Zoghbi H. Y., Orr H. T., Ataxin-1 nuclear localization and aggregation: role in polyglutarnine- induced disease in SCA1 transgenic mice. Cell 1998 95 1 41 53 10.1016/S0092-8674(00)81781-X 2-s2.0-0032475941
12. Huynh D. P., Figueroa K., Hoang N., Pulst S.-M., Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nature Genetics 2000 26 1 44 50 10.1038/79162 2-s2.0-0033811788
13. Goti D., Katzen S. M., Mez J., Kurtis N., Kiluk J., Ben-Haïem L., Jenkins N. A., Copeland N. G., Kakizuka A., Sharp A. H., Ross C. A., Mouton P. R., Colomer V., A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. Journal of Neuroscience 2004 24 45 10266 10279 10.1523/JNEUROSCI.2734-04.2004 2-s2.0-20844462057
14. Colomer Gould V. F., Goti D., Pearce D., Gonzalez G. A., Gao H., Bermudez de Leon M., Jenkins N. A., Copeland N. G., Ross C. A., Brown D. R., A Mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice. Neurobiology of Disease 2007 27 3 362 369 10.1016/j.nbd.2007.06.005 2-s2.0-34548329581
15. Kubodera T., Yokota T., Ohwada K., Ishikawa K., Miura H., Matsuoka T., Mizusawa H., Proteolytic cleavage and cellular toxicity of the human &1A calcium channel in spinocerebellar ataxia type 6. Neuroscience Letters 2003 341 1 74 78 10.1016/S0304-3940(03)00156-3 2-s2.0-0037464386
16. Yvert G., Lindenberg K. S., Picaud S., Landwehrmeyer G. B., Sahel J.-A., Mandel J.-L., Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice. Human Molecular Genetics 2000 9 17 2491 2506 10.1093/hmg/9.17.2491 2-s2.0-0034641891
17. Garden G. A., Libby R. T., Fu Y.-H., Kinoshita Y., Huang J., Possin D. E., Smith A. C., Martinez R. A., Fine G. C., Grote S. K., Ware C. B., Einum D. D., Morrison R. S., Ptacek L. J., Sopher B. L., La Spada A. R., Polyglutamine-expanded ataxin-7 promotes non-cell-autonomous purkinje cell degeneration and displays proteolytic cleavage in ataxic transgenic mice. Journal of Neuroscience 2002 22 12 4897 4905 2-s2.0-0037096365
18. Friedman M. J., Wang C.-E., Li X.-J., Li S., Polyglutamine expansion reduces the association of TATA-binding protein with DNA and induces DNA binding-independent neurotoxicity. Journal of Biological Chemistry 2008 283 13 8283 8290 10.1074/jbc.M709674200 2-s2.0-43749091298
19. Gutekunst C.-A., Li S.-H., Yi H., Mulroy J. S., Kuemmerle S., Jones R., Rye D., Ferrante R. J., Hersch S. M., Li X.-J., Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. Journal of Neuroscience 1999 19 7 2522 2534 2-s2.0-0033119123
20. Kim Y. J., Yi Y., Sapp E., Wang Y., Cuiffo B., Kegel K. B., Qin Z.-H., Aronin N., DiFiglia M., Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpaindependent proteolysis. Proceedings of the National Academy of Sciences of the United States of America 2001 98 22 12784 12789 10.1073/pnas.221451398 2-s2.0-0035940412
21. Goldberg Y. P., Nicholson D. W., Rasper D. M., Kalchman M. A., Koide H. B., Graham R. K., Bromm M., Kazemi-Esfarjani P., Thornberry N. A., Vaillancourt J. P., Hayden M. R., Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nature Genetics 1996 13 4 442 449 10.1038/ng0896-442 2-s2.0-9344227302
22. Wellington C. L., Ellerby L. M., Hackam A. S., Margolis R. L., Trifiro M. A., Singaraja R., McCutcheon K., Salvesen G. S., Propp S. S., Bromm M., Rowland K. J., Zhang T., Rasper D., Roy S., Thornberry N., Pinsky L., Kakizuka A., Ross C. A., Nicholson D. W., Bredesen D. E., Hayden M. R., Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. Journal of Biological Chemistry 1998 273 15 9158 9167 10.1074/jbc.273.15.9158 2-s2.0-0032502715
23. Wellington C. L., Ellerby L. M., Gutekunst C.-A., Rogers D., Warby S., Graham R. K., Loubser O., Van Raamsdonk J., Singaraja R., Yang Y.-Z., Gafni J., Bredesen D., Hersch S. M., Leavitt B. R., Roy S., Nicholson D. W., Hayden M. R., Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. Journal of Neuroscience 2002 22 18 7862 7872 2-s2.0-0037107151
24. Young J. E., Gouw L., Propp S., Sopher B. L., Taylor J., Lin A., Hermel E., Logvinova A., Chen S. F., Chen S., Bredesen D. E., Truant R., Ptacek L. J., La Spada A. R., Ellerby L. M., Proteolytic cleavage of ataxin-7 by caspase-7 modulates cellular toxicity and transcriptional dysregulation. Journal of Biological Chemistry 2007 282 41 30150 30160 10.1074/jbc.M705265200 2-s2.0-35648964788
25. Gafni J., Ellerby L. M., Calpain Activation in Huntington's Disease. Journal of Neuroscience 2002 22 12 4842 4849 2-s2.0-0037096376
26. Gafni J., Hermel E., Young J. E., Wellington C. L., Hayden M. R., Ellerby L. M., Inhibition of calpain cleavage of Huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. Journal of Biological Chemistry 2004 279 19 20211 20220 10.1074/jbc.M401267200 2-s2.0-2442631459
27. Goffredo D., Rigamonti D., Tartari M., De Micheli A., Verderio C., Matteoli M., Zuccato C., Cattaneo E., Calcium-dependent cleavage of endogenous wild-type huntingtin in primary cortical neurons. Journal of Biological Chemistry 2002 277 42 39594 39598 10.1074/jbc.C200353200 2-s2.0-0037131263
28. Haacke A., Hartl F. U., Breuer P., Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3. Journal of Biological Chemistry 2007 282 26 18851 18856 10.1074/jbc.M611914200 2-s2.0-34547129609
29. Hübener J., Weber J. J., Richter C., Honold L., Weiss A., Murad F., Breuer P., Wüllner U., Bellstedt P., Paquet-Durand F., Takano J., Saido T. C., Riess O., Nguyen H. P., Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3). Human Molecular Genetics 2013 22 3 508 518 10.1093/hmg/dds449 2-s2.0-84872416147
30. Nozaki K., Onodera O., Takano H., Tsuji S., Amino acid sequences flanking polyglutamine stretches influence their potential for aggregate formation. NeuroReport 2001 12 15 3357 3364 10.1097/00001756-200110290-00042 2-s2.0-0035968933
31. Ng H., Pulst S.-M., Huynh D. P., Ataxin-2 mediated cell death is dependent on domains downstream of the polyQ repeat. Experimental Neurology 2007 208 2 207 215 10.1016/j.expneurol.2007.07.023 2-s2.0-36049003085
32. Paulson H. L., Perez M. K., Trottier Y., Trojanowski J. Q., Subramony S. H., Das S. S., Vig P., Mandel J.-L., Fischbeck K. H., Pittman R. N., Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 1997 19 2 333 344 10.1016/S0896-6273(00)80943-5 2-s2.0-0030850412
33. Haacke A., Broadley S. A., Boteva R., Tzvetkov N., Hartl F. U., Breuer P., Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3. Human Molecular Genetics 2006 15 4 555 568 10.1093/hmg/ddi472 2-s2.0-32144436256
34. Hackam A. S., Singaraja R., Wellington C. L., Metzler M., McCutcheon K., Zhang T., Kalchman M., Hayden M. R., The influence of huntingtin protein size on nuclear localization and cellular toxicity. Journal of Cell Biology 1998 141 5 1097 1105 10.1083/jcb.141.5.1097 2-s2.0-0032101287
35. Martindale D., Hackam A., Wieczorek A., Ellerby L., Wellington C., McCutcheon K., Singaraja R., Kazemi-Esfarjani P., Devon R., Kim S. U., Bredesen D. E., Tufaro F., Hayden M. R., Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nature Genetics 1998 18 2 150 154 10.1038/ng0298-150 2-s2.0-17344363559
36. Toneff T., Mende-Mueller L., Wu Y., Hwang S.-R., Bundey R., Thompson L. M., Chesselet M.-F., Hook V., Comparison of huntingtin proteolytic fragments in human lymphoblast cell lines and human brain. Journal of Neurochemistry 2002 82 1 84 92 10.1046/j.1471-4159.2002.00940.x 2-s2.0-0036314167
37. DiFiglia M., Sapp E., Chase K. O., Davies S. W., Bates G. P., Vonsattel J. P., Aronin N., Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997 277 5334 1990 1993 10.1126/science.277.5334.1990 2-s2.0-0030752709
38. Schmidt T., Bernhard Landwehrmeyer G., Schmitt I., Trottier Y., Auburger G., Laccone F., Klockgether T., Völpel M., Epplen J. T., Schöls L., Riess O., An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. Brain Pathology 1998 8 4 669 679 10.1111/j.1750-3639.1998.tb00193.x 2-s2.0-7344234800
39. Sieradzan K. A., Mechan A. O., Jones L., Wanker E. E., Nukina N., Mann D. M. A., Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Experimental Neurology 1999 156 1 92 99 10.1006/exnr.1998.7005 2-s2.0-0033037919
40. Slow E. J., Graham R. K., Osmand A. P., Devon R. S., Lu G., Deng Y., Pearson J., Vaid K., Bissada N., Wetzel R., Leavitt B. R., Hayden M. R., Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proceedings of the National Academy of Sciences of the United States of America 2005 102 32 11402 11407 10.1073/pnas.0503634102 2-s2.0-23844472610
41. Hübener J., Vauti F., Funke C., Wolburg H., Ye Y., Schmidt T., Wolburg-Buchholz K., Schmitt I., Gardyan A., Drießen S., Arnold H.-H., Nguyen H. P., Riess O., N-terminal ataxin-3 causes neurological symptoms with inclusions, endoplasmic reticulum stress and ribosomal dislocation. Brain 2011 134 7 1925 1942 10.1093/brain/awr118 2-s2.0-79959694745
42. Li J., Yuan J., Caspases in apoptosis and beyond. Oncogene 2008 27 48 6194 6206 10.1038/onc.2008.297 2-s2.0-54249096028
43. McIlwain D. R., Berger T., Mak T. W., Caspase functions in cell death and disease. Cold Spring Harbor Perspectives in Biology 2013 5 4 a008656 10.1101/cshperspect.a008656 2-s2.0-84884785095
44. Chen M., Ona V. O., Li M., Ferrante R. J., Fink K. B., Zhu S., Bian J., Guo L., Farrell L. A., Hersch S. M., Hobbs W., Vonsattei J.-P., Cha J.-H. J., Friedlander R. M., Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nature Medicine 2000 6 7 797 801 10.1038/77528 2-s2.0-0033912716
45. Hermel E., Gafni J., Propp S. S., Leavitt B. R., Wellington C. L., Young J. E., Hackam A. S., Logvinova A. V., Peel A. L., Chen S. F., Hook V., Singaraja R., Krajewski S., Goldsmith P. C., Ellerby H. M., Hayden M. R., Bredesen D. E., Ellerby L. M., Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death and Differentiation 2004 11 4 424 438 10.1038/sj.cdd.4401358 2-s2.0-11144357398
46. Kim M., Lee H.-S., LaForet G., McIntyre C., Martin E. J., Chang P., Kim T. W., Williams M., Reddy P. H., Tagle D., Boyce F. M., Won L., Heller A., Aronin N., DiFiglia M., Mutant Huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. Journal of Neuroscience 1999 19 3 964 973 2-s2.0-0033081766
47. Portera-Cailliau C., Hedreen J. C., Price D. L., Koliatsos V. E., Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. Journal of Neuroscience 1995 15 5 3775 3787 2-s2.0-0029072690
48. Lunkes A., Mandel J.-L., A cellular model that recapitulates major pathogenic steps of Huntington's disease. Human Molecular Genetics 1998 7 9 1355 1361 10.1093/hmg/7.9.1355 2-s2.0-0031680014
49. Ona V. O., Li M., Vonsattel J. P. G., John Andrews L., Khan S. Q., Chung W. M., Frey A. S., Menon A. S., Li X.-J., Stieg P. E., Yuan J., Penney J. B., Young A. B., Cha J.-H. J., Friedlander R. M., Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 1999 399 6733 263 267 10.1038/20446 2-s2.0-0033587128
50. Li S.-H., Lam S., Cheng A. L., Li X.-J., Intranuclear huntingtin increases the expression of caspase-1 and induces apoptosis. Human Molecular Genetics 2000 9 19 2859 2867 10.1093/hmg/9.19.2859 2-s2.0-0034703874
51. Zhang Y., Ona V. O., Li M., Drozda M., Dubois-Dauphin M., Przedborski S., Ferrante R. J., Friedlander R. M., Sequential activation of individual caspases, and of alterations in Bcl-2 proapoptotic signals in a mouse model of Huntington's disease. Journal of Neurochemistry 2003 87 5 1184 1192 10.1046/j.1471-4159.2003.02105.x 2-s2.0-0344010993
52. Davies S. W., Turmaine M., Cozens B. A., DiFiglia M., Sharp A. H., Ross C. A., Scherzinger E., Wanker E. E., Mangiarini L., Bates G. P., Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997 90 3 537 548 10.1016/S0092-8674(00)80513-9 2-s2.0-18544410106
53. Chou A.-H., Yeh T.-H., Kuo Y.-L., Kao Y.-C., Jou M.-J., Hsu C.-Y., Tsai S.-R., Kakizuka A., Wang H.-L., Polyglutamine-expanded ataxin-3 activates mitochondrial apoptotic pathway by upregulating Bax and downregulating Bcl-xL. Neurobiology of Disease 2006 21 2 333 345 10.1016/j.nbd.2005.07.011 2-s2.0-30744474942
54. Zander C., Takahashi J., El Hachimi K. H., Fujigasaki H., Albanese V., Lebre A. S., Stevanin G., Duyckaerts C., Brice A., Similarities between spinocerebellar ataxia type 7 (SCA7) cell models and human brain: Proteins recruited in inclusions and activation of caspase-3. Human Molecular Genetics 2001 10 22 2569 2579 10.1093/hmg/10.22.2569 2-s2.0-0035888620
55. Latouche M., Lasbleiz C., Martin E., Monnier V., Debeir T., Mouatt-Prigent A., Muriel M.-P., Morel L., Ruberg M., Brice A., Stevanin G., Tricoire H., A conditional pan-neuronal Drosophila model of spinocerebellar ataxia 7 with a reversible adult phenotype suitable for identifying modifier genes. Journal of Neuroscience 2007 27 10 2483 2492 10.1523/JNEUROSCI.5453-06.2007 2-s2.0-33847769390
56. Graham R. K., Deng Y., Carroll J., Vaid K., Cowan C., Pouladi M. A., Metzler M., Bissada N., Wang L., Faull R. L. M., Gray M., Yang X. W., Raymond L. A., Hayden M. R., Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo. Journal of Neuroscience 2010 30 45 15019 15029 10.1523/JNEUROSCI.2071-10.2010 2-s2.0-78149487690
57. Graham R. K., Deng Y., Slow E. J., Haigh B., Bissada N., Lu G., Pearson J., Shehadeh J., Bertram L., Murphy Z., Warby S. C., Doty C. N., Roy S., Wellington C. L., Leavitt B. R., Raymond L. A., Nicholson D. W., Hayden M. R., Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006 125 6 1179 1191 10.1016/j.cell.2006.04.026 2-s2.0-33745003424
58. Milnerwood A. J., Gladding C. M., Pouladi M. A., Kaufman A. M., Hines R. M., Boyd J. D., Ko R. W. Y., Vasuta O. C., Graham R. K., Hayden M. R., Murphy T. H., Raymond L. A., Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 2010 65 2 178 190 10.1016/j.neuron.2010.01.008 2-s2.0-74549181538
59. Gafni J., Papanikolaou T., Degiacomo F., Holcomb J., Chen S., Menalled L., Kudwa A., Fitzpatrick J., Miller S., Ramboz S., Tuunanen P. I., Lehtimäki K. K., Yang X. W., Park L., Kwak S., Howland D., Park H., Ellerby L. M., Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment. Journal of Neuroscience 2012 32 22 7454 7465 10.1523/JNEUROSCI.6379-11.2012 2-s2.0-84861630493
60. Landles C., Weiss A., Franklin S., Howland D., Bates G. P., Caspase-6 does not contribute to the proteolysis of mutant huntingtin in the HdhQ150 Knock-in mouse model of Huntington's disease. PLoS Currents 2012 e4fd085bfc9973 10.1371/4fd085bfc9973 2-s2.0-84867459264
61. Berke S. J., Schmied F. A., Brunt E. R., Ellerby L. M., Paulson H. L., Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3. Journal of Neurochemistry 2004 89 4 908 918 10.1111/j.1471-4159.2004.02369.x 2-s2.0-2542445545
62. Pozzi C., Valtorta M., Tedeschi G., Galbusera E., Pastori V., Bigi A., Nonnis S., Grassi E., Fusi P., Study of subcellular localization and proteolysis of ataxin-3. Neurobiology of Disease 2008 30 2 190 200 10.1016/j.nbd.2008.01.011 2-s2.0-42649132458
63. Jung J., Xu K., Lessing D., Bonini N. M., Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3. Human Molecular Genetics 2009 18 24 4843 4852 10.1093/hmg/ddp456 2-s2.0-70450191208
64. Liman J., Deeg S., Voigt A., Voßfeldt H., Dohm C. P., Karch A., Weishaupt J., Schulz J. B., Bähr M., Kermer P., CDK5 protects from caspase-induced ataxin-3 cleavage and neurodegeneration. Journal of Neurochemistry 2014 129 6 1013 1023 10.1111/jnc.12684 2-s2.0-84896583584
65. Koch P., Breuer P., Peitz M., Jungverdorben J., Kesavan J., Poppe D., Doerr J., Ladewig J., Mertens J., Tüting T., Hoffmann P., Klockgether T., Evert B. O., Wüllner U., Brüstle O., Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature 2011 480 7378 543 546 10.1038/nature10671 2-s2.0-84355161952
66. Sorimachi H., Hata S., Ono Y., Calpain chronicle-an enzyme family under multidisciplinary characterization. Proceedings of the Japan Academy Series B: Physical and Biological Sciences 2011 87 6 287 327 10.2183/pjab.87.287 2-s2.0-79959301027
67. Smith M. A., Schnellmann R. G., Calpains, mitochondria, and apoptosis. Cardiovascular Research 2012 96 1 32 37 10.1093/cvr/cvs163 2-s2.0-84866685475
68. Cowan C. M., Fan M. M. Y., Fan J., Shehadeh J., Zhang L. Y. J., Graham R. K., Hayden M. R., Raymond L. A., Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity. Journal of Neuroscience 2008 28 48 12725 12735 2-s2.0-58149373434 10.1523/JNEUROSCI.4619-08.2008
69. Gladding C. M., Sepers M. D., Xu J., Zhang L. Y. J., Milnerwood A. J., Lombroso P. J., Raymond L. A., Calpain and STriatal-Enriched protein tyrosine Phosphatase (STEP) activation contribute to extrasynaptic NMDA receptor localization in a huntington's disease mouse model. Human Molecular Genetics 2012 21 17 3739 3752 10.1093/hmg/dds154 2-s2.0-84865078592
70. Dau A., Gladding C. M., Sepers M. D., Raymond L. A., Chronic blockade of extrasynaptic NMDA receptors ameliorates synaptic dysfunction and pro-death signaling in Huntington disease transgenic mice. Neurobiology of Disease 2014 62 533 542 10.1016/j.nbd.2013.11.013 2-s2.0-84890027845
71. Landles C., Sathasivam K., Weiss A., Woodman B., Moffitt H., Finkbeiner S., Sun B., Gafni J., Ellerby L. M., Trottier Y., Richards W. G., Osmand A., Paganetti P., Bates G. P., Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in huntington disease. Journal of Biological Chemistry 2010 285 12 8808 8823 10.1074/jbc.M109.075028 2-s2.0-77950584656
72. Schilling B., Gafni J., Torcassi C., Cong X., Row R. H., LaFevre-Bernt M. A., Cusack M. P., Ratovitski T., Hirschhorn R., Ross C. A., Gibson B. W., Ellerby L. M., Huntingtin phosphorylation sites mapped by mass spectrometry: modulation of cleavage and toxicity. Journal of Biological Chemistry 2006 281 33 23686 23697 10.1074/jbc.M513507200 2-s2.0-33747633422
73. Kim M., Roh J.-K., Yoon B. W., Kang L., Kim Y. J., Aronin N., DiFiglia M., Huntingtin is degraded to small fragments by calpain after ischemic injury. Experimental Neurology 2003 183 1 109 115 10.1016/S0014-4886(03)00132-8 2-s2.0-0042190049
74. Simões A. T., Gonçalves N., Koeppen A., Déglon N., Kügler S., Duarte C. B., Pereira De Almeida L., Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease. Brain 2012 135 8 2428 2439 10.1093/brain/aws177 2-s2.0-84864658791
75. Kim Y. J., Sapp E., Cuiffo B. G., Sobin L., Yoder J., Kegel K. B., Qin Z.-H., Detloff P., Aronin N., DiFiglia M., Lysosomal proteases are involved in generation of N-terminal huntingtin fragments. Neurobiology of Disease 2006 22 2 346 356 10.1016/j.nbd.2005.11.012 2-s2.0-33646121970
76. Qin Z.-H., Wang Y., Kegel K. B., Kazantsev A., Apostol B. L., Thompson L. M., Yoder J., Aronin N., DiFiglia M., Autophagy regulates the processing of amino terminal huntingtin fragments. Human Molecular Genetics 2003 12 24 3231 3244 10.1093/hmg/ddg346 2-s2.0-0348013126
77. Ratovitski T., Chighladze E., Waldron E., Hirschhorn R. R., Ross C. A., Cysteine proteases bleomycin hydrolase and cathepsin Z mediate N-terminal proteolysis and toxicity of mutant huntingtin. Journal of Biological Chemistry 2011 286 14 12578 12589 10.1074/jbc.M110.185348 2-s2.0-79953325705
78. Lunkes A., Lindenberg K. S., Ben-Haem L., Weber C., Devys D., Landwehrmeyer G. B., Mandel J.-L., Trottier Y., Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Molecular Cell 2002 10 2 259 269 10.1016/S1097-2765(02)00602-0 2-s2.0-0036671821
79. Kegel K. B., Sapp E., Alexander J., Reeves P., Bleckmann D., Sobin L., Masso N., Valencia A., Jeong H., Krainc D., Palacino J., Curtis D., Kuhn R., Betschart C., Sena-Esteves M., Aronin N., Paganetti P., Difiglia M., Huntingtin cleavage product A forms in neurons and is reduced by gamma-secretase inhibitors. Molecular Neurodegeneration 2010 5 1, article 58 10.1186/1750-1326-5-58 2-s2.0-78650035000
80. Miller J. P., Holcomb J., Al-Ramahi I., de Haro M., Gafni J., Zhang N., Kim E., Sanhueza M., Torcassi C., Kwak S., Botas J., Hughes R. E., Ellerby L. M., Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease. Neuron 2010 67 2 199 212 10.1016/j.neuron.2010.06.021 2-s2.0-77955500335
81. Sathasivam K., Neueder A., Gipson T. A., Landles C., Benjamin A. C., Bondulich M. K., Smith D. L., Faull R. L. M., Roos R. A. C., Howland D., Detloff P. J., Housman D. E., Bates G. P., Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America 2013 110 6 2366 2370 10.1073/pnas.1221891110 2-s2.0-84873463075
82. Mauri P. L., Riva M., Ambu D., De Palma A., Secundo F., Benazzi L., Valtorta M., Tortora P., Fusi P., Ataxin-3 is subject to autolytic cleavage. The FEBS Journal 2006 273 18 4277 4286 10.1111/j.1742-4658.2006.05419.x 2-s2.0-33748319345
83. Wellington C. L., Singaraja R., Ellerby L., Savill J., Roy S., Leavitt B., Cattaneo E., Hackam A., Sharp A., Thornberry N., Nicholson D. W., Bredesen D. E., Hayden M. R., Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. Journal of Biological Chemistry 2000 275 26 19831 19838 10.1074/jbc.M001475200 2-s2.0-0034733607
84. Ratovitski T., Nakamura M., D'Ambola J., Chighladze E., Liang Y., Wang W., Graham R., Hayden M. R., Borchelt D. R., Hirschhorn R. R., Ross C. A., N-terminal proteolysis of full-length mutant huntingtin in an inducible PC12 cell model of Huntington's disease. Cell Cycle 2007 6 23 2970 2981 10.4161/cc.6.23.4992 2-s2.0-37549065909
85. Sancho M., Herrera A. E., Gortat A., Carbajo R. J., Pineda-Lucena A., Orzáez M., Pérez-Payá E., Minocycline inhibits cell death and decreases mutant Huntingtin aggregation by targeting Apaf-1. Human Molecular Genetics 2011 20 18 3545 3553 10.1093/hmg/ddr271 2-s2.0-80052243629
86. Luo S., Vacher C., Davies J. E., Rubinsztein D. C., Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity. Journal of Cell Biology 2005 169 4 647 656 10.1083/jcb.200412071 2-s2.0-22344439156
87. Evers M. M., Tran H.-D., Zalachoras I., Meijer O. C., Den Dunnen J. T., Van Ommen G.-J. B., Aartsma-Rus A., Van Roon-Mom W. M. C., Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification. Nucleic Acid Therapeutics 2014 24 1 4 12 10.1089/nat.2013.0452 2-s2.0-84893555011
88. Becher M. W., Kotzuk J. A., Sharp A. H., Davies S. W., Bates G. P., Price D. L., Ross C. A., Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiology of Disease 1998 4 6 387 397 10.1006/nbdi.1998.0168 2-s2.0-0031918640
89. Skinner P. J., Koshy B. T., Cummings C. J., Klement I. A., Helin K., Servadio A., Zoghbi H. Y., Orr H. T., Ataxin-1 with an expanded glutamine tract alters nuclear matrix- associated structures. Nature 1997 389 6654 971 974 10.1038/40153 2-s2.0-0030666001
90. Ishikawa K., Fujigasaki H., Saegusa H., Ohwada K., Fujita T., Iwamoto H., Komatsuzaki Y., Toru S., Toriyama H., Watanabe M., Ohkoshi N., Shoji S., Kanazawa I., Tanabe T., Mizusawa H., Abundant expression and cytoplasmic aggregations of &1A voltage-dependent calcium channel protein associated with neurodegeneration in spinocerebellar ataxia type 6. Human Molecular Genetics 1999 8 7 1185 1193 10.1093/hmg/8.7.1185 2-s2.0-0032769095
91. Takahashi J., Fujigasaki H., Zander C., El Hachimi K. H., Stevanin G., Dürr A., Lebre A.-S., Yvert G., Trottier Y., De Thé H., Hauw J.-J., Duyckaerts C., Brice A., Two populations of neuronal intranuclear inclusions in SCA7 differ in size and promyelocytic leukaemia protein content. Brain 2002 125 7 1534 1543 10.1093/brain/awf154 2-s2.0-0036317942
92. Nakamura K., Jeong S.-Y., Uchihara T., Anno M., Nagashima K., Nagashima T., Ikeda S.-I., Tsuji S., Kanazawa I., SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Human Molecular Genetics 2001 10 14 1441 1448 10.1093/hmg/10.14.1441 2-s2.0-0035393427
93. Durr A., Smadja D., Cancel G., Lezin A., Stevanin G., Mikol J., Bellance R., Buisson G.-G., Chneiweiss H., Dellanave J., Agid Y., Brice A., Vernant J.-C., Autosomal dominant cerebellar ataxia type I in Martinique (French West Indies). Clinical and neuropathological analysis of 53 patients from three unrelated SCA2 families. Brain 1995 118 6 1573 1581 10.1093/brain/118.6.1573 2-s2.0-0029611008
94. Huynh D. P., Del Bigio M. R., Ho D. H., Pulst S. M., Expression of ataxin-2 in brains from normal individuals and patients with Alzheimer's disease and spinocerebellar ataxia 2. Annals of Neurology 1999 45 2 232 241 10.1002/1531-8249(199902)45:2<232::AID-ANA14>3.0.CO;2-7
95. Koyano S., Uchihara T., Fujigasaki H., Nakamura A., Yagishita S., Iwabuchi K., Neuronal intranuclear inclusions in spinocerebellar ataxia type 2: triple-labeling immunofluorescent study. Neuroscience Letters 1999 273 2 117 120 10.1016/S0304-3940(99)00656-4 2-s2.0-0032840052
96. Pang J. T., Giunti P., Chamberlain S., An S. F., Vitaliani R., Scaravilli T., Martinian L., Wood N. W., Scaravilli F., Ansorge O., Neuronal intranuclear inclusions in SCA2: a genetic, morphological and immunohistochemical study of two cases. Brain 2002 125 3 656 663 10.1093/brain/awf060 2-s2.0-0036185711
97. Kodali R., Wetzel R., Polymorphism in the intermediates and products of amyloid assembly. Current Opinion in Structural Biology 2007 17 1 48 57 10.1016/j.sbi.2007.01.007 2-s2.0-33846160381
98. Jayaraman M., Thakur A. K., Kar K., Kodali R., Wetzel R., Assays for studying nucleated aggregation of polyglutamine proteins. Methods 2011 53 3 246 254 10.1016/j.ymeth.2011.01.001 2-s2.0-79952189175
99. Ellisdon A. M., Thomas B., Bottomley S. P., The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step. Journal of Biological Chemistry 2006 281 25 16888 16896 10.1074/jbc.M601470200 2-s2.0-33745195252
100. Stöhr J., Prion protein aggregation and fibrillogenesis in vitro. Sub-cellular biochemistry 2012 65 91 108 10.1007/978-94-007-5416-4-5 2-s2.0-84894469743
101. Jayaraman M., Mishra R., Kodali R., Thakur A. K., Koharudin L. M. I., Gronenborn A. M., Wetzel R., Kinetically competing huntingtin aggregation pathways control amyloid polymorphism and properties. Biochemistry 2012 51 13 2706 2716 10.1021/bi3000929 2-s2.0-84859400325
102. Pellistri F., Bucciantini M., Invernizzi G., Gatta E., Penco A., Frana A. M., Nosi D., Relini A., Regonesi M. E., Gliozzi A., Tortora P., Robello M., Stefani M., Different ataxin-3 amyloid aggregates induce intracellular Ca2+ deregulation by different mechanisms in cerebellar granule cells. Biochimica et Biophysica Acta-Molecular Cell Research 2013 1833 12 3155 3165 10.1016/j.bbamcr.2013.08.019 2-s2.0-84884920984
103. Kuemmerle S., Gutekunst C. A., Klein A. M., Li X. J., Li S. H., Beal M. F., Hersch S. M., Ferrante R. J., Huntington aggregates may not predict neuronal death in Huntingtons disease. Annals of Neurology 1999 46 6 842 849
104. Sen S., Dash D., Pasha S., Brahmachari S. K., Role of histidine interruption in mitigating the pathological effects of long polyglutamine stretches in SCA1: a molecular approach. Protein Science 2003 12 5 953 962 10.1110/ps.0224403 2-s2.0-0037406093
105. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J., Taddei N., Ramponi G., Dobson C. M., Stefani M., Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002 416 6880 507 511 10.1038/416507a 2-s2.0-0037041420
106. Weiss A., Klein C., Woodman B., Sathasivam K., Bibel M., Régulier E., Bates G. P., Paganetti P., Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. Journal of Neurochemistry 2008 104 3 846 858 10.1111/j.1471-4159.2007.05032.x 2-s2.0-38049139425
107. Seidel K., Brunt E. R. P., de Vos R. A. I., Dijk F., van der Want H. J. L., Kampinga H. H., Rüb U., den Dunnen W. F. A., The p62 antibody reveals various cytoplasmic protein aggregates in spinocerebellar ataxia Type 6. Clinical Neuropathology 2009 28 5 344 349 10.5414/NPP28344 2-s2.0-70350041634
108. Nekooki-Machida Y., Kurosawa M., Nukina N., Ito K., Oda T., Tanaka M., Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America 2009 106 24 9679 9684 10.1073/pnas.0812083106 2-s2.0-67649856863
109. Yang W., Dunlap J. R., Andrews R. B., Wetzel R., Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Human Molecular Genetics 2002 11 23 2905 2917 2-s2.0-0036850529
110. Ren P.-H., Lauckner J. E., Kachirskaia I., Heuser J. E., Melki R., Kopito R. R., Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nature Cell Biology 2009 11 2 219 225 10.1038/ncb1830 2-s2.0-59649095699
111. Iuchi S., Hoffner G., Verbeke P., Djian P., Green H., Oligomeric and polymeric aggregates formed by proteins containing expanded polyglutamine. Proceedings of the National Academy of Sciences of the United States of America 2003 100 5 2409 2414 10.1073/pnas.0437660100 2-s2.0-0345701297
112. Takahashi T., Kikuchi S., Katada S., Nagai Y., Nishizawa M., Onodera O., Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. Human Molecular Genetics 2008 17 3 345 356 10.1093/hmg/ddm311 2-s2.0-38349158062
113. Legleiter J., Mitchell E., Lotz G. P., Sapp E., Ng C., DiFiglia M., Thompson L. M., Muchowski P. J., Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo. Journal of Biological Chemistry 2010 285 19 14777 14790 10.1074/jbc.M109.093708 2-s2.0-77951988103
114. Sathasivam K., Lane A., Legleiter J., Warley A., Woodman B., Finkbeiner S., Paganetti P., Muchowski P. J., Wilson S., Bates G. P., Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease. Human Molecular Genetics 2009 19 1 65 78 10.1093/hmg/ddp467 2-s2.0-77649297870
115. Jackson W. S., Tallaksen-Greene S. J., Albin R. L., Detloff P. J., Nucleocytoplasmic transport signals affect the age at onset of abnormalities in knock-in mice expressing polyglutamine within an ectopic protein context. Human Molecular Genetics 2003 12 13 1621 1629 10.1093/hmg/ddg163 2-s2.0-0038104366
116. Bichelmeier U., Schmidt T., Hübener J., Boy J., Rüttiger L., Häbig K., Poths S., Bonin M., Knipper M., Schmidt W. J., Wilbertz J., Wolburg H., Laccone F., Riess O., Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3:in vivo evidence. Journal of Neuroscience 2007 27 28 7418 7428 10.1523/JNEUROSCI.4540-06.2007 2-s2.0-34447520352
117. Ribbeck K., Görlich D., The permeability barrier of nuclear pore complexes appears to operate via hydrophobic exclusion. The EMBO Journal 2002 21 11 2664 2671 10.1093/emboj/21.11.2664 2-s2.0-0037013954
118. Pemberton L. F., Paschal B. M., Mechanisms of receptor-mediated nuclear import and nuclear export. Traffic 2005 6 3 187 198 10.1111/j.1600-0854.2005.00270.x 2-s2.0-14544299215
119. Kaytor M. D., Duvick L. A., Skinner P. J., Koob M. D., Ranum L. P. W., Orr H. T., Nuclear localization of the spinocerebellar ataxia type 7 protein, ataxin-7. Human Molecular Genetics 1999 8 9 1657 1664 10.1093/hmg/8.9.1657 2-s2.0-0032858212
120. Xia J., Lee D. H., Taylor J., Vandelft M., Truant R., Huntingtin contains a highly conserved nuclear export signal. Human Molecular Genetics 2003 12 12 1393 1403 10.1093/hmg/ddg156 2-s2.0-0037701612
121. Irwin S., Vandelft M., Pinchev D., Howell J. L., Graczyk J., Orr H. T., Truant R., RNA association and nucleocytoplasmic shuttling by ataxin-1. Journal of Cell Science 2005 118 1 233 242 10.1242/jcs.01611 2-s2.0-14044266141
122. Taylor J., Grote S. K., Xia J., Vandelft M., Graczyk J., Ellerby L. M., La Spada A. R., Truant R., Ataxin-7 can export from the nucleus via a conserved exportin-dependent signal. Journal of Biological Chemistry 2006 281 5 2730 2739 10.1074/jbc.M506751200 2-s2.0-33646378692
123. Antony P. M. A., Mäntele S., Mollenkopf P., Boy J., Kehlenbach R. H., Riess O., Schmidt T., Identification and functional dissection of localization signals within ataxin-3. Neurobiology of Disease 2009 36 2 280 292 10.1016/j.nbd.2009.07.020 2-s2.0-70349780383
124. Lai S., O'Callaghan B., Zoghbi H. Y., Orr H. T., 14-3-3 Binding to ataxin-1(ATXN1) regulates its dephosphorylation at Ser-776 and transport to the nucleus. Journal of Biological Chemistry 2011 286 40 34606 34616 10.1074/jbc.M111.238527 2-s2.0-80053405457
125. Lim J., Crespo-Barreto J., Jafar-Nejad P., Bowman A. B., Richman R., Hill D. E., Orr H. T., Zoghbi H. Y., Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 2008 452 7188 713 718 10.1038/nature06731 2-s2.0-42049086100
126. Peters M. F., Nucifora F. C. Jr., Kushi J., Seaman H. C., Cooper J. K., Herring W. J., Dawson V. L., Dawson T. M., Ross C. A., Nuclear targeting of mutant huntingtin increases toxicity. Molecular and Cellular Neurosciences 1999 14 2 121 128 10.1006/mcne.1999.0773 2-s2.0-0032847708
127. Saudou F., Finkbeiner S., Devys D., Greenberg M. E., Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998 95 1 55 56 10.1016/S0092-8674(00)81782-1 2-s2.0-0032475931
128. Schilling G., Savonenko A. V., Klevytska A., Morton J. L., Tucker S. M., Poirier M., Gale A., Chan N., Gonzales V., Slunt H. H., Coonfield M. L., Jenkins N. A., Copeland N. G., Ross C. A., Borchelt D. R., Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice. Human Molecular Genetics 2004 13 15 1599 1610 10.1093/hmg/ddh175 2-s2.0-4344636957
129. Atwal R. S., Xia J., Pinchev D., Taylor J., Epand R. M., Truant R., Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Human Molecular Genetics 2007 16 21 2600 2615 10.1093/hmg/ddm217 2-s2.0-35448994487
130. Reina C. P., Zhong X., Pittman R. N., Proteotoxic stress increases nuclear localization of ataxin-3. Human Molecular Genetics 2009 19 2 235 249 10.1093/hmg/ddp482 2-s2.0-77949450752
131. Munsie L., Caron N., Atwal R. S., Marsden I., Wild E. J., Bamburg J. R., Tabrizi S. J., Truant R., Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease. Human Molecular Genetics 2011 20 10 1937 1951 10.1093/hmg/ddr075 2-s2.0-79955456732
132. Maiuri T., Woloshansky T., Xia J., Truant R., The huntingtin N17 domain is a multifunctional CRM1 and ran-dependent nuclear and cilial export signal. Human Molecular Genetics 2013 22 7 1383 1394 10.1093/hmg/dds554 2-s2.0-84873340106
133. Watkin E. E., Arbez N., Waldron-Roby E., O'Meally R., Ratovitski T T., Cole R. N., Ross C. A., Phosphorylation of mutant huntingtin at serine 116 modulates neuronal toxicity. PLoS ONE 2014 9 2 e88284
134. Mueller T., Breuer P., Schmitt I., Walter J., Evert B. O., Wüllner U., CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3. Human Molecular Genetics 2009 18 17 3334 3343 10.1093/hmg/ddp274 2-s2.0-68749103450
135. Chan W. M., Tsoi H., Wu C. C., Wong C. H., Cheng T. C., Li H. Y., Lau K. F., Shaw P. C., Perrimon N., Chan H. Y. E., Expanded polyglutamine domain possesses nuclear export activity which modulates subcellular localization and toxicity of polyQ disease protein via exportin-1. Human Molecular Genetics 2011 20 9 1738 1750 10.1093/hmg/ddr049 2-s2.0-79954464577
136. Desmond C. R., Atwal R. S., Xia J., Truant R., Identification of a karyopherin β 1/ β 2 proline-tyrosine nuclear localization signal in huntingtin protein. The Journal of Biological Chemistry 2012 287 47 39626 39633 10.1074/jbc.M112.412379 2-s2.0-84873947122
137. Patel V. P., Chu C. T., Nuclear transport, oxidative stress, and neurodegeneration. International Journal of Clinical and Experimental Pathology 2011 4 3 215 229 2-s2.0-80051632945
138. Katsuno M., Tanaka F., Adachi H., Banno H., Suzuki K., Watanabe H., Sobue G., Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA). Progress in Neurobiology 2012 99 3 246 256 10.1016/j.pneurobio.2012.05.007 2-s2.0-84869870525
139. Montie H. I., Cho M. S., Holder L., Liu Y., Tsvetkov A. S., Finkbeiner S., Merry D. E., Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Human Molecular Genetics 2009 18 11 1937 1950 10.1093/hmg/ddp115 2-s2.0-65549163327
140. Koyano S., Yagishita S., Kuroiwa Y., Tanaka F., Uchihara T., Neuropathological staging of spinocerebellar ataxia type 2 by semiquantitative 1C2-positive neuron typing. Nuclear translocation of cytoplasmic 1C2 underlies disease progression of spinocerebellar ataxia type 2. Brain Pathology 2014 10.1111/bpa.12146 2-s2.0-84901101574
141. Elden A. C., Kim H.-J., Hart M. P., Chen-Plotkin A. S., Johnson B. S., Fang X., Armakola M., Geser F., Greene R., Lu M. M., Padmanabhan A., Clay-Falcone D., McCluskey L., Elman L., Juhr D., Gruber P. J., Rüb U., Auburger G., Trojanowski J. Q., Lee V. M.-Y., Van Deerlin V. M., Bonini N. M., Gitler A. D., Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 2010 466 7310 1069 1075 10.1038/nature09320 2-s2.0-77956155218
142. Lessing D., Bonini N. M., Polyglutamine genes interact to modulate the severity and progression of neurodegeneration in Drosophila. PLoS Biology 2008 6 2, article e29 0266 0274 10.1371/journal.pbio.0060029 2-s2.0-40149101562
143. 2+ channel &1A subunits translocate to nuclei and promote polyglutamine-mediated toxicity. Human Molecular Genetics 2006 15 10 1587 1599 10.1093/hmg/ddl080 2-s2.0-33745207300
144. Cornett J., Cao F., Wang C.-E., Ross C. A., Bates G. P., Li S.-H., Li X.-J., Polyglutamine expansion of huntingtin impairs its nuclear export. Nature Genetics 2005 37 2 198 204 10.1038/ng1503 2-s2.0-13944275615
145. Chai Y., Shao J., Miller V. M., Williams A., Paulson H. L., Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis. Proceedings of the National Academy of Sciences of the United States of America 2002 99 14 9310 9315 10.1073/pnas.152101299 2-s2.0-0037047123
146. Chu C. T., Plowey E. D., Wang Y., Patel V., Jordan-Sciutto K. L., Location, location, location: altered transcription factor trafficking in neurodegeneration. Journal of Neuropathology and Experimental Neurology 2007 66 10 873 883 10.1097/nen.0b013e318156a3d7 2-s2.0-34948841925
147. Yorimitsu T., Klionsky D. J., Autophagy: molecular machinery for self-eating. Cell Death and Differentiation 2005 12 supplement 2 1542 1552 10.1038/sj.cdd.4401765 2-s2.0-27644484061
148. Ciechanover A., The ubiquitin proteolytic system: From a vague idea, through basic mechanisms, and onto human diseases and drug targeting. Neurology 2006 66 2 S7 S19 10.1212/01.wnl.0000192261.02023.b8 2-s2.0-33644859083
149. Wickner S., Maurizi M. R., Gottesman S., Posttranslational quality control: folding, refolding, and degrading proteins. Science 1999 286 5446 1888 1893 10.1126/science.286.5446.1888 2-s2.0-0033520987
150. Kästle M., Grune T., Interactions of the proteasomal system with chaperones: protein triage and protein quality control. Progress in Molecular Biology and Translational Science 2012 109 113 160 10.1016/B978-0-12-397863-9.00004-3 2-s2.0-84862742197
151. Wang G.-H., Sawai N., Kotliarova S., Kanazawa I., Nukina N., Ataxin-3, the MJD1 gene product, interacts with the two human homologs of yeast DNA repair protein RAD23, HHR23A and HHR23B. Human Molecular Genetics 2000 9 12 1795 1803 10.1093/hmg/9.12.1795 2-s2.0-0033867992
152. Doss-Pepe E. W., Stenroos E. S., Johnson W. G., Madura K., Ataxin-3 interactions with Rad23 and valosin-containing protein and its associations with ubiquitin chains and the proteasome are consistent with a role in ubiquitin-mediated proteolysis. Molecular and Cellular Biology 2003 23 18 6469 6483 10.1128/MCB.23.18.6469-6483.2003 2-s2.0-0042691818
153. Davidson J. D., Riley B., Burright E. N., Duvick L. A., Zoghbi H. Y., Orr H. T., Identification and characterization of an ataxin-1-interacting protein: A1Up, a ubiquitin-like nuclear protein. Human Molecular Genetics 2000 9 15 2305 2312 10.1093/oxfordjournals.hmg.a018922 2-s2.0-0034703397
154. Hong S., Kim S.-J., Ka S., Choi I., Kang S., USP7, a ubiquitin-specific protease, interacts with ataxin-1, the SCA1 gene product. Molecular and Cellular Neuroscience 2002 20 2 298 306 10.1006/mcne.2002.1103 2-s2.0-0036311587
155. Hong S., Lee S., Cho S.-G., Kang S., UbcH6 interacts with and ubiquitinates the SCA1 gene product ataxin-1. Biochemical and Biophysical Research Communications 2008 371 2 256 260 10.1016/j.bbrc.2008.04.066 2-s2.0-43149123766
156. Lee S., Hong S., Kang S., The ubiquitin-conjugating enzyme UbcH6 regulates the transcriptional repression activity of the SCA1 gene product ataxin-1. Biochemical and Biophysical Research Communications 2008 372 4 735 740 10.1016/j.bbrc.2008.05.125 2-s2.0-46149116525
157. Matilla A., Gorbea C., Einum D. D., Townsend J., Michalik A., Van Broeckhoven C., Jensen C. C., Murphy K. J., Ptácek L. J., Fu Y.-H., Association of ataxin-7 with the proteasome subunit S4 of the 19S regulatory complex. Human Molecular Genetics 2001 10 24 2821 2831 10.1093/hmg/10.24.2821 2-s2.0-0035891863
158. Waelter S., Boeddrich A., Lurz R., Scherzinger E., Lueder G., Lehrach H., Wanker E. E., Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Molecular Biology of the Cell 2001 12 5 1393 1407 10.1091/mbc.12.5.1393 2-s2.0-0034754875
159. Arrasate M., Finkbeiner S., Protein aggregates in Huntington's disease. Experimental Neurology 2012 238 1 1 11 10.1016/j.expneurol.2011.12.013 2-s2.0-84866556522
160. Cummings C. J., Mancini M. A., Antalffy B., DeFranco D. B., Orr H. T., Zoghbi H. Y., Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nature Genetics 1998 19 2 148 154 10.1038/502 2-s2.0-0031838352
161. Schmidt T., Lindenberg K. S., Krebs A., Schöls L., Laccone F., Herms J., Rechsteiner M., Riess O., Landwehrmeyer B., Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions. Annals of Neurology 2002 51 3 302 310 10.1002/ana.10101 2-s2.0-0036198110
162. Rosser M. F. N., Washburn E., Muchowski P. J., Patterson C., Cyr D. M., Chaperone functions of the E3 ubiquitin ligase CHIP. Journal of Biological Chemistry 2007 282 31 22267 22277 10.1074/jbc.M700513200 2-s2.0-34547958064
163. Jana N. R., Dikshit P., Goswami A., Kotliarova S., Murata S., Tanaka K., Nukina N., Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. Journal of Biological Chemistry 2005 280 12 11635 11640 10.1074/jbc.M412042200 2-s2.0-15744387323
164. Al-Ramahi I., Lam Y. C., Chen H.-K., De Gouyon B., Zhang M., Pérez A. M., Branco J., De Haro M., Patterson C., Zoghbi H. Y., Botas J., CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation. Journal of Biological Chemistry 2006 281 36 26714 26724 10.1074/jbc.M601603200 2-s2.0-33748741301
165. Williams A. J., Knutson T. M., Colomer Gould V. F., Paulson H. L., In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis. Neurobiology of Disease 2009 33 3 342 353 10.1016/j.nbd.2008.10.016 2-s2.0-60849119525
166. Choi J. Y., Ryu J. H., Kim H.-S., Park S. G., Bae K.-H., Kang S., Myung P. K., Cho S., Park B. C., Lee D. H., Co-chaperone CHIP promotes aggregation of ataxin-1. Molecular and Cellular Neuroscience 2007 34 1 69 79 10.1016/j.mcn.2006.10.002 2-s2.0-33845864451
167. Morishima Y., Wang A. M., Yu Z., Pratt W. B., Osawa Y., Lieberman A. P., CHIP deletion reveals functional redundancy of E3 ligases in promoting degradation of both signaling proteins and expanded glutamine proteins. Human Molecular Genetics 2008 17 24 3942 3952 10.1093/hmg/ddn296 2-s2.0-57049117002
168. Tsai Y. C., Fishman P. S., Thakor N. V., Oyler G. A., Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. Journal of Biological Chemistry 2003 278 24 22044 22055 10.1074/jbc.M212235200 2-s2.0-0038159253
169. Huynh D. P., Nguyen D. T., Pulst-Korenberg J. B., Brice A., Pulst S.-M., Parkin is an E3 ubiquitin-ligase for normal and mutant ataxin-2 and prevents ataxin-2-induced cell death. Experimental Neurology 2007 203 2 531 541 10.1016/j.expneurol.2006.09.009 2-s2.0-33846545106
170. Durcan T. M., Kontogiannea M., Thorarinsdottir T., Fallon L., Williams A. J., Djarmati A., Fantaneanu T., Paulson H. L., Fon E. A., The machado-joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability. Human Molecular Genetics 2011 20 1 141 154 10.1093/hmg/ddq452 2-s2.0-79955964218
171. Durcan T. M., Kontogiannea M., Bedard N., Wing S. S., Fon E. A., Ataxin-3 deubiquitination is coupled to parkin ubiquitination via E2 ubiquitin-conjugating enzyme. Journal of Biological Chemistry 2012 287 1 531 541 10.1074/jbc.M111.288449 2-s2.0-84855287943
172. Rubio I., Rodríguez-Navarro J. A., Tomás-Zapico C., Ruíz C., Casarejos M. J., Perucho J., Gómez A., Rodal I., Lucas J. J., Mena M. A., de Yébenes J. G., Effects of partial suppression of parkin on huntingtin mutant R6/1 mice. Brain Research 2009 1281 91 100 10.1016/j.brainres.2009.05.039 2-s2.0-67649411510
173. Kalchman M. A., Graham R. K., Xia G., Brook Koide H., Graeme Hodgson J., Graham K. C., Paul Goldberg Y., Dan Gietz R., Pickart C. M., Hayden M. R., Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. Journal of Biological Chemistry 1996 271 32 19385 19394 10.1074/jbc.271.32.19385 2-s2.0-9444239187
174. de Pril R., Fischer D. F., Roos R. A. C., van Leeuwen F. W., Ubiquitin-conjugating enzyme E2-25K increases aggregate formation and cell death in polyglutamine diseases. Molecular and Cellular Neuroscience 2007 34 1 10 19 10.1016/j.mcn.2006.09.006 2-s2.0-33845898194
175. Weinhofer I., Forss-Petter S., Žigman M., Berger J., Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Human Molecular Genetics 2002 11 22 2689 2700 10.1093/hmg/11.22.2689 2-s2.0-0037108725
176. Jana N. R., Zemskov E. A., Wang G.-H., Nukina N., Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Human Molecular Genetics 2001 10 10 1049 1059 10.1093/hmg/10.10.1049 2-s2.0-0035336658
177. Seo H., Sonntag K.-C., Isacson O., Generalized brain and skin proteasome inhibition in Huntington's disease. Annals of Neurology 2004 56 3 319 328 10.1002/ana.20207 2-s2.0-4444303263
178. Park Y., Hong S., Kim S.-J., Kang S., Proteasome function is inhibited by polyglutamine-expanded ataxin-1, the SCA1 gene product. Molecules and Cells 2005 19 1 23 30 2-s2.0-22844451581
179. Díaz-Hernández M., Valera A. G., Morán M. A., Gómez-Ramos P., Alvarez-Castelao B., Castaño J. G., Hernández F., Lucas J. J., Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain. Journal of Neurochemistry 2006 98 5 1585 1596 10.1111/j.1471-4159.2006.03968.x 2-s2.0-33746932115
180. Khan L. A., Bauer P. O., Miyazaki H., Lindenberg K. S., Landwehrmeyer B. G., Nukina N., Expanded polyglutamines impair synaptic transmission and ubiquitin-proteasome system in Caenorhabditis elegans. Journal of Neurochemistry 2006 98 2 576 587 10.1111/j.1471-4159.2006.03895.x 2-s2.0-33746487396
181. Wang H.-L., He C.-Y., Chou A.-H., Yeh T.-H., Chen Y.-L., Li A. H., Polyglutamine-expanded ataxin-7 decreases nuclear translocation of NF- B p65 and impairs NF- B activity by inhibiting proteasome activity of cerebellar neurons. Cellular Signalling 2007 19 3 573 581 10.1016/j.cellsig.2006.08.006 2-s2.0-33846220180
182. Yang S., Huang S., Gaertig M. A., Li X.-J., Li S., Age-dependent decrease in chaperone activity impairs MANF expression, leading to Purkinje cell degeneration in inducible SCA17 mice. Neuron 2014 81 2 349 365 10.1016/j.neuron.2013.12.002 2-s2.0-84892768191
183. Bowman A. B., Yoo S.-Y., Dantuma N. P., Zoghbi H. Y., Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation. Human Molecular Genetics 2005 14 5 679 691 10.1093/hmg/ddi064 2-s2.0-14644419638
184. Juenemann K., Schipper-Krom S., Wiemhoefer A., Kloss A., Sanz A. S., Reits E. A. J., Expanded polyglutamine-containing N-terminal huntingtin fragments are entirely degraded by mammalian proteasomes. Journal of Biological Chemistry 2013 288 38 27068 27084 10.1074/jbc.M113.486076 2-s2.0-84884567375
185. Schipper-Krom S., Juenemann K., Jansen A. H., Wiemhoefer A., Van Den Nieuwendijk R., Smith D. L., Hink M. A., Bates G. P., Overkleeft H., Ovaa H., Reits E., Dynamic recruitment of active proteasomes into polyglutamine initiated inclusion bodies. The FEBS Letters 2014 588 1 151 159 10.1016/j.febslet.2013.11.023 2-s2.0-84890988864
186. Wyttenbach A., Carmichael J., Swartz J., Furlong R. A., Narain Y., Rankin J., Rubinsztein D. C., Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America 2000 97 6 2898 2903 10.1073/pnas.97.6.2898 2-s2.0-0034646426
187. Wang H., Jia N., Fei E., Wang Z., Liu C., Zhang T., Fan J., Wu M., Chen L., Nukina N., Zhou J., Wang G., p45, an ATPase subunit of the 19S proteasome, targets the polyglutamine disease protein ataxin-3 to the proteasome. Journal of Neurochemistry 2007 101 6 1651 1661 10.1111/j.1471-4159.2007.04460.x 2-s2.0-34249807884
188. Venkatraman P., Wetzel R., Tanaka M., Nukina N., Goldberg A. L., Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Molecular Cell 2004 14 1 95 104 10.1016/S1097-2765(04)00151-0 2-s2.0-1842766144
189. Holmberg C. I., Staniszewski K. E., Mensah K. N., Matouschek A., Morimoto R. I., Inefficient degradation of truncated polyglutamine proteins by the proteasome. The EMBO Journal 2004 23 21 4307 4318 10.1038/sj.emboj.7600426 2-s2.0-9144223729
190. Pratt G., Rechsteiner M., Proteasomes cleave at multiple sites within polyglutamine tracts: activation by PA28 γ (K188E). Journal of Biological Chemistry 2008 283 19 12919 12925 10.1074/jbc.M709347200 2-s2.0-45149115090
191. Ravikumar B., Duden R., Rubinsztein D. C., Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Human Molecular Genetics 2002 11 9 1107 1117 10.1093/hmg/11.9.1107 2-s2.0-0036566266
192. Mookerjee S., Papanikolaou T., Guyenet S. J., Sampath V., Lin A., Vitelli C., DeGiacomo F., Sopher B. L., Chen S. F., La Spada A. R., Ellerby L. M., Posttranslational modification of ataxin-7 at lysine 257 prevents autophagy-mediated turnover of an N-terminal caspase-7 cleavage fragment. Journal of Neuroscience 2009 29 48 15134 15144 10.1523/JNEUROSCI.4720-09.2009 2-s2.0-72849148037
193. Metzger S., Saukko M., Van Che H., Tong L., Puder Y., Riess O., Nguyen H. P., Age at onset in Huntington's disease is modified by the autophagy pathway: implication of the V471A polymorphism in Atg7. Human Genetics 2010 128 4 453 459 10.1007/s00439-010-0873-9 2-s2.0-77957565855
194. Metzger S., Walter C., REGISTRY Investigators of the European Huntington's Disease Network, Riess O., Roos R. A. C., Nielsen J. E., Craufurd D., Nguyen H. P., The V471A polymorphism in autophagy-related gene ATG7 modifies age at onset specifically in Italian Huntington disease patients. PLoS ONE 2013 8 7 e68951 10.1371/journal.pone.0068951 2-s2.0-84880667166
195. Iwata A., Christianson J. C., Bucci M., Ellerby L. M., Nukina N., Forno L. S., Kopito R. R., Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. Proceedings of the National Academy of Sciences of the United States of America 2005 102 37 13135 13140 10.1073/pnas.0505801102 2-s2.0-24944482408
196. Duncan C., Papanikolaou T., Ellerby L. M., Autophagy: polyQ toxic fragment turnover. Autophagy 2010 6 2 312 314 10.4161/auto.6.2.11139 2-s2.0-77953489549
197. Yu X., Ajayi A., Boga N. R., Ström A.-L., Differential degradation of full-length and cleaved ataxin-7 fragments in a novel stable inducible SCA7 model. Journal of Molecular Neuroscience 2012 47 2 219 233 10.1007/s12031-012-9722-8 2-s2.0-84863870150
198. Unno T., Wakamori M., Koike M., Uchiyama Y., Ishikawa K., Kubota H., Yoshida T., Sasakawa H., Peters C., Mizusawa H., Watase K., Development of Purkinje cell degeneration in a knockin mouse model reveals lysosomal involvement in the pathogenesis of SCA6. Proceedings of the National Academy of Sciences of the United States of America 2012 109 43 17693 17698 10.1073/pnas.1212786109 2-s2.0-84867908880
199. Nascimento-Ferreira I., Santos-Ferreira T., Sousa-Ferreira L., Auregan G., Onofre I., Alves S., Dufour N., Colomer Gould V. F., Koeppen A., Déglon N., Pereira De Almeida L., Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease. Brain 2011 134 5 1400 1415 10.1093/brain/awr047 2-s2.0-79957458183
200. Nascimento-Ferreira I., Nóbrega C., Vasconcelos-Ferreira A., Onofre I., Albuquerque D., Aveleira C., Hirai H., Déglon N., Pereira De Almeida L., Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado-Joseph disease. Brain 2013 136 7 2173 2188 10.1093/brain/awt144 2-s2.0-84879899999
201. Sapp E., Schwarz C., Chase K., Bhide P. G., Young A. B., Penney J., Vonsattel J. P., Aronin N., DiFiglia M., Huntingtin localization in brains of normal and Huntington's disease patients. Annals of Neurology 1997 42 4 604 612 10.1002/ana.410420411 2-s2.0-0030771894
202. Petersén Å., Larsen K. E., Behr G. G., Romero N., Przedborski S., Brundin P., Sulzer D., Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration. Human Molecular Genetics 2001 10 12 1243 1254 10.1093/hmg/10.12.1243 2-s2.0-0035364748
203. Nagata E., Sawa A., Ross C. A., Snyder S. H., Autophagosome-like vacuole formation in Huntington's disease lymphoblasts. NeuroReport 2004 15 8 1325 1328 10.1097/01.wnr.0000127073.66692.8f 2-s2.0-2942527227
204. Vig P. J. S., Shao Q., Subramony S. H., Lopez M. E., Safaya E., Bergmann glial S100B activates myo-inositol monophosphatase 1 and Co-localizes to Purkinje cell vacuoles in SCA1 transgenic mice. Cerebellum 2009 8 3 231 244 10.1007/s12311-009-0125-5 2-s2.0-69549088145
205. Yu X., Muñoz-Alarcón A., Ajayi A., Webling K. E., Steinhof A., Langel Ü., Ström A.-L., Inhibition of autophagy via p53-mediated disruption of ULK1 in a SCA7 polyglutamine disease model. Journal of Molecular Neuroscience 2013 50 3 586 599 10.1007/s12031-013-0012-x 2-s2.0-84878934829
206. Pankiv S., Clausen T. H., Lamark T., Brech A., Bruun J.-A., Outzen H., Øvervatn A., Bjørkøy G., Johansen T., p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. Journal of Biological Chemistry 2007 282 33 24131 24145 10.1074/jbc.M702824200 2-s2.0-34548259958
207. Nagaoka U., Kim K., Nihar R. J., Doi H., Maruyama M., Mitsui K., Oyama F., Nukina N., Increased expression of p62 in expanded polyglutamine-expressing cells and its association with polyglutamine inclusions. Journal of Neurochemistry 2004 91 1 57 68 10.1111/j.1471-4159.2004.02692.x 2-s2.0-4744349602
208. Seidel K., Den Dunnen W. F. A., Schultz C., Paulson H., Frank S., De Vos R. A., Brunt E. R., Deller T., Kampinga H. H., Rüb U., Axonal inclusions in spinocerebellar ataxia type 3. Acta Neuropathologica 2010 120 4 449 460 10.1007/s00401-010-0717-7 2-s2.0-77956183748
209. Pankiv S., Lamark T., Bruun J.-A., Øvervatn A., Bjørkøy G., Johansen T., Nucleocytoplasmic shuttling of p62/SQSTM1 and its role in recruitment of nuclear polyubiquitinated proteins to promyelocytic leukemia bodies. Journal of Biological Chemistry 2010 285 8 5941 5953 10.1074/jbc.M109.039925 2-s2.0-77949324195
210. Bhutani N., Venkatraman P., Goldberg A. L., Puromycin-sensitive aminopeptidase is the major peptidase responsible for digesting polyglutamine sequences released by proteasomes during protein degradation. The EMBO Journal 2007 26 5 1385 1396 10.1038/sj.emboj.7601592 2-s2.0-33947164372
211. Menzies F. M., Hourez R., Imarisio S., Raspe M., Sadiq O., Chandraratna D., O'Kane C., Rock K. L., Reits E., Goldberg A. L., Rubinsztein D. C., Puromycin-sensitive aminopeptidase protects against aggregation-prone proteins via autophagy. Human Molecular Genetics 2010 19 23 4573 4586 10.1093/hmg/ddq385 2-s2.0-78149277418
212. Muchowski P. J., Schaffar G., Sittler A., Wanker E. E., Hayer-Hartl M. K., Hartl F. U., Hsp70 and Hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proceedings of the National Academy of Sciences of the United States of America 2000 97 14 7841 7846 10.1073/pnas.140202897 2-s2.0-0034608868
213. Friedman M. J., Li S., Li X.-J., Activation of gene transcription by heat shock protein 27 may contribute to its neuronal protection. Journal of Biological Chemistry 2009 284 41 27944 27951 10.1074/jbc.M109.037937 2-s2.0-70350432944
214. Krobitsch S., Lindquist S., Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proceedings of the National Academy of Sciences of the United States of America 2000 97 4 1589 1594 10.1073/pnas.97.4.1589 2-s2.0-0034652127
215. Satyal S. H., Schmidt E., Kitagawa K., Sondheimer N., Lindquist S., Kramer J. M., Morimoto R. I., Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proceedings of the National Academy of Sciences of the United States of America 2000 97 11 5750 5755 10.1073/pnas.100107297 2-s2.0-0034705224
216. Warrick J. M., Chan H. Y. E., Gray-Board G. L., Chai Y., Paulson H. L., Bonini N. M., Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nature Genetics 1999 23 4 425 428 10.1038/70532 2-s2.0-0032727617
217. Jana N. R., Tanaka M., Wang G.-H., Nukina N., Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Human Molecular Genetics 2000 9 13 2009 2018 10.1093/hmg/9.13.2009 2-s2.0-0034641589
218. Zhou H., Li S.-H., Li X.-J., Chaperone suppression of cellular toxicity of huntingtin is independent of polyglutamine aggregation. Journal of Biological Chemistry 2001 276 51 48417 48424 2-s2.0-0035930598
219. Wyttenbach A., Sauvageot O., Carmichael J., Diaz-Latoud C., Arrigo A.-P., Rubinsztein D. C., Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Human Molecular Genetics 2002 11 9 1137 1151 10.1093/hmg/11.9.1137 2-s2.0-0036566675
220. Cummings C. J., Sun Y., Opal P., Antalffy B., Mestril R., Orr H. T., Dillmann W. H., Zoghbi H. Y., Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Human Molecular Genetics 2001 10 14 1511 1518 10.1093/hmg/10.14.1511 2-s2.0-0035394668
221. Hansson O., Nylandsted J., Castilho R. F., Leist M., Jäättelä M., Brundin P., Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression. Brain Research 2003 970 1-2 47 57 10.1016/S0006-8993(02)04275-0 2-s2.0-0347928859
222. Hay D. G., Sathasivam K., Tobaben S., Stahl B., Marber M., Mestril R., Mahal A., Smith D. L., Woodman B., Bates G. P., Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Human Molecular Genetics 2004 13 13 1389 1405 10.1093/hmg/ddh144 2-s2.0-3242695184
223. Fujimoto M., Takaki E., Hayashi T., Kitaura Y., Tanaka Y., Inouye S., Nakai A., Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models. Journal of Biological Chemistry 2005 280 41 34908 34916 10.1074/jbc.M506288200 2-s2.0-27144524290
224. Vacher C., Garcia-Oroz L., Rubinsztein D. C., Overexpression of yeast hsp104 reduces polyglutamine aggregation and prolongs survival of a transgenic mouse model of Huntington's disease. Human Molecular Genetics 2005 14 22 3425 3433 10.1093/hmg/ddi372 2-s2.0-27944499891
225. Perrin V., Régulier E., Abbas-Terki T., Hassig R., Brouillet E., Aebischer P., Luthi-Carter R., Déglon N., Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease. Molecular Therapy 2007 15 5 903 911 10.1038/mt.sj.6300141 2-s2.0-34247245632
226. Zourlidou A., Gidalevitz T., Kristiansen M., Landles C., Woodman B., Wells D. J., Latchman D. S., de Belleroche J., Tabrizi S. J., Morimoto R. I., Bates G. P., Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: Chronic neurodegeneration does not induce Hsp27 activation. Human Molecular Genetics 2007 16 9 1078 1090 10.1093/hmg/ddm057 2-s2.0-34447331291
227. Fujikake N., Nagai Y., Popiel H. A., Okamoto Y., Yamaguchi M., Toda T., Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. Journal of Biological Chemistry 2008 283 38 26188 26197 10.1074/jbc.M710521200 2-s2.0-54449101793
228. Yi J., Zhang L., Tang B., Han W., Zhou Y., Chen Z., Jia D., Jiang H., Sodium valproate alleviates neurodegeneration in SCA3/MJD via suppressing apoptosis and rescuing the hypoacetylation levels of histone H3 and H4. PLoS ONE 2013 8 1 e54792 10.1371/journal.pone.0054792 2-s2.0-84873874848
229. Zádori D., Geisz A., Vámos E., Vécsei L., Klivényi P., Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease. Pharmacology Biochemistry and Behavior 2009 94 1 148 153 10.1016/j.pbb.2009.08.001 2-s2.0-70349195820
230. Chiu C.-T., Liu G., Leeds P., Chuang D.-M., Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of huntington's disease. Neuropsychopharmacology 2011 36 12 2406 2421 10.1038/npp.2011.128 2-s2.0-80054772539
231. Unti E., Mazzucchi S., Kiferle L., Bonuccelli U., Ceravolo R., Q09 & Valproic Acid for the treatment of aggressiveness in Huntington's disease: 1-year follow-up. Journal of Neurology, Neurosurgery & Psychiatry 2012 83 A57 10.1136/jnnp-2012-303524.179
232. Salazar Z., Tschopp L., Calandra C., Micheli F., Pisa syndrome and Parkinson secondary to valproic acid in Huntington's disease. Movement Disorders 2008 23 16 2430 2431 10.1002/mds.22328 2-s2.0-61449125123
233. Chou A.-H., Chen S.-Y., Yeh T.-H., Weng Y.-H., Wang H.-L., HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3. Neurobiology of Disease 2011 41 2 481 488 10.1016/j.nbd.2010.10.019 2-s2.0-78650613146
234. Gardian G., Browne S. E., Choi D.-K., Klivenyi P., Gregorio J., Kubilus J. K., Ryu H., Langley B., Ratan R. R., Ferrante R. J., Beal M. F., Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. Journal of Biological Chemistry 2005 280 1 556 563 10.1074/jbc.M410210200 2-s2.0-19944431703
235. Hogarth P., Lovrecic L., Krainc D., Sodium phenylbutyrate in Huntington's disease: a dose-finding study. Movement Disorders 2007 22 13 1962 1964 10.1002/mds.21632 2-s2.0-36248970599
236. Watson L. M., Scholefield J., Jacquie Greenberg L., Wood M. J. A., Polyglutamine disease: from pathogenesis to therapy. South African Medical Journal 2012 102 6 481 484 2-s2.0-84865114423
237. Silva-Fernandes A., Duarte-Silva S., Neves-Carvalho A., Amorim M., Soares-Cunha C., Oliveira P., Thirstrup K., Teixeira-Castro A., Maciel P., Chronic Treatment with 17-DMAG Improves Balance and Coordination in A New Mouse Model of Machado-Joseph Disease. Neurotherapeutics 2014 11 2 433 449 10.1007/s13311-013-0255-9 2-s2.0-84899493975
238. Wu J.-C., Qi L., Wang Y., Kegel K. B., Yoder J., Difiglia M., Qin Z.-H., Lin F., The regulation of N-terminal Huntingtin (Htt552) accumulation by Beclin1. Acta Pharmacologica Sinica 2012 33 6 743 751 10.1038/aps.2012.14 2-s2.0-84862547657
239. Ravikumar B., Vacher C., Berger Z., Davies J. E., Luo S., Oroz L. G., Scaravilli F., Easton D. F., Duden R., O'Kane C. J., Rubinsztein D. C., Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nature Genetics 2004 36 6 585 595 10.1038/ng1362 2-s2.0-2642586352
240. Berger Z., Ttofi E. K., Michel C. H., Pasco M. Y., Tenant S., Rubinsztein D. C., O'Kane C. J., Lithium rescues toxicity of aggregate-prone proteins in Drosophila by perturbing Wnt pathway. Human Molecular Genetics 2005 14 20 3003 3011 10.1093/hmg/ddi331 2-s2.0-27544497472
241. Menzies F. M., Huebener J., Renna M., Bonin M., Riess O., Rubinsztein D. C., Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. Brain 2010 133 1 93 104 10.1093/brain/awp292 2-s2.0-74249103961
242. Sarkar S., Rubinsztein D. C., Inositol and IP3 levels regulate autophagy: biology and therapeutic speculations. Autophagy 2006 2 2 132 134 10.4161/auto.2387 2-s2.0-33645916698
243. Carmichael J., Sugars K. L., Bao Y. P., Rubinsztein D. C., Glycogen synthase kinase-3 β inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. Journal of Biological Chemistry 2002 277 37 33791 33798 10.1074/jbc.M204861200 2-s2.0-0037072807
244. Watase K., Gatchel J. R., Sun Y., Emamian E., Atkinson R., Richman R., Mizusawa H., Orr H. T., Shaw C., Zoghbi H. Y., Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Medicine 2007 4 5, article e182 0836 0847 10.1371/journal.pmed.0040182 2-s2.0-34249675397
245. Jia D.-D., Zhang L., Chen Z., Wang C.-R., Huang F.-Z., Duan R.-H., Xia K., Tang B.-S., Jiang H., Lithium chloride alleviates neurodegeneration partly by inhibiting activity of GSK3 β in a SCA3 drosophila model. Cerebellum 2013 12 6 892 901 10.1007/s12311-013-0498-3 2-s2.0-84892431753
246. Wu S., Zheng S.-D., Huang H.-L., Yan L.-C., Yin X.-F., Xu H.-N., Zhang K.-J., Gui J.-H., Chu L., Liu X.-Y., Lithium down-regulates histone deacetylase 1 (HDAC1) and induces degradation of mutant huntingtin. Journal of Biological Chemistry 2013 288 49 35500 35510 10.1074/jbc.M113.479865 2-s2.0-84894355071
247. Sarkar S., Krishna G., Imarisio S., Saiki S., O'Kane C. J., Rubinsztein D. C., A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Human Molecular Genetics 2008 17 2 170 178 10.1093/hmg/ddm294 2-s2.0-37849042536
248. Rose C., Menzies F. M., Renna M., Acevedo-Arozena A., Corrochano S., Sadiq O., Brown S. D., Rubinsztein D. C., Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease. Human Molecular Genetics 2010 19 11 2144 2153 10.1093/hmg/ddq093 2-s2.0-77953486943
249. Sarkar S., Davies J. E., Huang Z., Tunnacliffe A., Rubinsztein D. C., Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and &-synuclein. Journal of Biological Chemistry 2007 282 8 5641 5652 10.1074/jbc.M609532200 2-s2.0-34247161367
250. Wei P.-F., Zhang L., Nethi S. K., Barui A. K., Lin J., Zhou W., Shen Y., Man N., Zhang Y.-J., Xu J., Patra C. R., Wen L.-P., Accelerating the clearance of mutant huntingtin protein aggregates through autophagy induction by europium hydroxide nanorods. Biomaterials 2014 35 3 899 907 10.1016/j.biomaterials.2013.10.024 2-s2.0-84887620690
251. Moura M. B., dos Santos L. S., van Houten B., Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environmental and Molecular Mutagenesis 2010 51 5 391 405 10.1002/em.20575 2-s2.0-77953500851
252. Tan W., Pasinelli P., Trotti D., Role of mitochondria in mutant SOD1 linked amyotrophic lateral sclerosis. Biochimica et Biophysica Acta-Molecular Basis of Disease 2014 1842 8 1295 1301 10.1016/j.bbadis.2014.02.009 2-s2.0-84895856178
253. Leenders K. L., Frackowiak R. S., Quinn N., Marsden C. D., Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography. Movement Disorders 1986 1 1 69 77 10.1002/mds.870010110 2-s2.0-0022946353
254. Djoussé L., Knowlton B., Cupples L. A., Marder K., Shoulson I., Myers R. H., Weight loss in early stage of Huntington's disease. Neurology 2002 59 9 1325 1330 10.1212/01.WNL.0000031791.10922.CF 2-s2.0-0037069280
255. Mähler A., Steiniger J., Endres M., Paul F., Boschmann M., Doss S., Increased catabolic state in spinocerebellar ataxia type 1 patients. Cerebellum 2014 1 7 10.1007/s12311-014-0555-6 2-s2.0-84894780640
256. Saute J. A. M., da Silva A. C. F., Souza G. N., Russo A. D., Donis K. C., Vedolin L., Saraiva-Pereira M. L., Portela L. V. C., Jardim L. B., Body mass index is inversely correlated with the expanded CAG repeat length in SCA3/MJD patients. Cerebellum 2012 11 3 771 774 10.1007/s12311-011-0326-6 2-s2.0-84864717629
257. Jafar-Nejad P., Ward C. S., Richman R., Orr H. T., Zoghbi H. Y., Regional rescue of spinocerebellar ataxia type 1 phenotypes by 14-3-3 ε haploinsufficiency in mice underscores complex pathogenicity in neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America 2011 108 5 2142 2147 10.1073/pnas.1018748108 2-s2.0-79952168998
258. Aziz N. A., Van Der Burg J. M. M., Landwehrmeyer G. B., Brundin P., Stijnen T., Roos R. A. C., Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 2008 71 19 1505 1513 2-s2.0-56149125562
259. Jenkins B. G., Koroshetz W. J., Beal M. F., Rosen B. R., Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 1993 43 12 2689 2695 10.1212/WNL.43.12.2689 2-s2.0-0027741301
260. Guerrini L., Lolli F., Ginestroni A., Belli G., Della Nave R., Tessa C., Foresti S., Cosottini M., Piacentini S., Salvi F., Plasmati R., De Grandis D., Siciliano G., Filla A., Mascalchi M., Brainstem neurodegeneration correlates with clinical dysfunction in SCA1 but not in SCA2. A quantitative volumetric, diffusion and proton spectroscopy MR study. Brain 2004 127 8 1785 1795 10.1093/brain/awh201 2-s2.0-4043130355
261. Öz G., Nelson C. D., Koski D. M., Henry P.-G., Marjańska M., Deelchand D. K., Shanley R., Eberly L. E., Orr H. T., Clark H. B., Noninvasive detection of presymptomatic and progressive neurodegeneration in a mouse model of spinocerebellar ataxia type 1. Journal of Neuroscience 2010 30 10 3831 3838 10.1523/JNEUROSCI.5612-09.2010 2-s2.0-77949371220
262. Emir U. E., Brent Clark H., Vollmers M. L., Eberly L. E., Öz G., Non-invasive detection of neurochemical changes prior to overt pathology in a mouse model of spinocerebellar ataxia type 1. Journal of Neurochemistry 2013 127 5 660 668 10.1111/jnc.12435 2-s2.0-84887605878
263. Costa V., Scorrano L., Shaping the role of mitochondria in the pathogenesis of Huntington's disease. The EMBO Journal 2012 31 8 1853 1864 10.1038/emboj.2012.65 2-s2.0-84859904873
264. Simon D. K., Zheng K., Velázquez L., Santos N., Almaguer L., Figueroa K. P., Pulst S.-M., Mitochondrial complex I gene variant associated with early age at onset in spinocerebellar ataxia type 2. Archives of Neurology 2007 64 7 1042 1044 10.1001/archneur.64.7.1042 2-s2.0-34447267684
265. Dagda R. K., Merrill R. A., Cribbs J. T., Chen Y., Hell J. W., Usachev Y. M., Strack S., The spinocerebellar ataxia 12 gene product and protein phosphatase 2A regulatory subunit B β 2 antagonizes neuronal survival by promoting mitochondrial fission. Journal of Biological Chemistry 2008 283 52 36241 36248 10.1074/jbc.M800989200 2-s2.0-60249095382
266. Yu Y.-C., Kuo C.-L., Cheng W.-L., Liu C.-S., Hsieh M., Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease. Journal of Neuroscience Research 2009 87 8 1884 1891 10.1002/jnr.22011 2-s2.0-66049150300
267. Wang Y.-C., Lee C.-M., Lee L.-C., Tung L.-C., Hsieh-Li H.-M., Lee-Chen G.-J., Su M.-T., Mitochondrial dysfunction and oxidative stress contribute to the pathogenesis of spinocerebellar ataxia type 12 (SCA12). Journal of Biological Chemistry 2011 286 24 21742 21754 10.1074/jbc.M110.160697 2-s2.0-79958723738
268. García-Martínez J. M., Pérez-Navarro E., Xifró X., Canals J. M., Díaz-Hernández M., Trioulier Y., Brouillet E., Lucas J. J., Alberch J., BH3-only proteins Bid and BimEL are differentially involved in neuronal dysfunction in mouse models of Huntington's disease. Journal of Neuroscience Research 2007 85 12 2756 2769 10.1002/jnr.21258 2-s2.0-34548361756
269. Laço M. N., Oliveira C. R., Paulson H. L., Rego A. C., Compromised mitochondrial complex II in models of Machado-Joseph disease. Acta Biochimica et Biophysica Sinica 2012 1822 2 139 149 10.1016/j.bbadis.2011.10.010 2-s2.0-83155185511
270. Pacheco L. S., da Silveira A. F., Trott A., Houenou L. J., Algarve T. D., Belló C., Lenz A. F., Mânica-Cattani M. F., da Cruz I. B. M., Association between Machado-Joseph disease and oxidative stress biomarkers. Mutation Research-Genetic Toxicology and Environmental Mutagenesis 2013 757 2 99 103 10.1016/j.mrgentox.2013.06.023 2-s2.0-84885850806
271. Chang K.-H., Chen W.-L., Wu Y.-R., Lin T.-H., Wu Y.-C., Chao C.-Y., Lin J.-Y., Lee L.-C., Chen Y.-C., Lee-Chen G.-J., Chen C.-M., Aqueous extract of Gardenia jasminoides targeting oxidative stress to reduce polyQ aggregation in cell models of spinocerebellar ataxia 3. Neuropharmacology 2014 81 166 175 10.1016/j.neuropharm.2014.01.032 2-s2.0-84896891344
272. Sugiura A., Yonashiro R., Fukuda T., Matsushita N., Nagashima S., Inatome R., Yanagi S., A mitochondrial ubiquitin ligase MITOL controls cell toxicity of polyglutamine-expanded protein. Mitochondrion 2011 11 1 139 146 10.1016/j.mito.2010.09.001 2-s2.0-78650007530
273. Panov A. V., Gutekunst C.-A., Leavitt B. R., Hayden M. R., Burke J. R., Strittmatter W. J., Greenamyre J. T., Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nature Neuroscience 2002 5 8 731 736 10.1038/nn884 2-s2.0-0036327065
274. Wang H.-L., Yeh T.-H., Chou A.-H., Kuo Y.-L., Luo L.-J., He C.-Y., Huang P.-C., Li A. H., Polyglutamine-expanded ataxin-7 activates mitochondrial apoptotic pathway of cerebellar neurons by upregulating Bax and downregulating Bcl-xL. Cellular Signalling 2006 18 4 541 552 10.1016/j.cellsig.2005.05.024 2-s2.0-29044445801
275. Wang H.-L., Chou A.-H., Lin A.-C., Chen S.-Y., Weng Y.-H., Yeh T.-H., Polyglutamine-expanded ataxin-7 upregulates Bax expression by activating p53 in cerebellar and inferior olivary neurons. Experimental Neurology 2010 224 2 486 494 10.1016/j.expneurol.2010.05.011 2-s2.0-77954659300
276. Chou A.-H., Lin A.-C., Hong K.-Y., Hu S.-H., Chen Y.-L., Chen J.-Y., Wang H.-L., P53 activation mediates polyglutamine-expanded ataxin-3 upregulation of Bax expression in cerebellar and pontine nuclei neurons. Neurochemistry International 2011 58 2 145 152 10.1016/j.neuint.2010.11.005 2-s2.0-78651254160
277. Bae B.-I., Xu H., Igarashi S., Fujimuro M., Agrawal N., Taya Y., Hayward S. D., Moran T. H., Montell C., Ross C. A., Snyder S. H., Sawa A., p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 2005 47 1 29 41 10.1016/j.neuron.2005.06.005 2-s2.0-21544450545
278. Vis J. C., Schipper E., de Boer-van H., Verbeek M. M., de Waal R. M. W., Wesseling P., ten Donkelaar H. J., Kremer B., Expression pattern of apoptosis-related markers in Huntington's disease. Acta Neuropathologica 2005 109 3 321 328 10.1007/s00401-004-0957-5 2-s2.0-23844440646
279. Tsai H.-F., Tsai H.-J., Hsieh M., Full-length expanded ataxin-3 enhances mitochondrial-mediated cell death and decreases Bcl-2 expression in human neuroblastoma cells. Biochemical and Biophysical Research Communications 2004 324 4 1274 1282 10.1016/j.bbrc.2004.09.192 2-s2.0-14344262672
280. Tien C.-L., Wen F.-C., Hsieh M., The polyglutamine-expanded protein ataxin-3 decreases bcl-2 mRNA stability. Biochemical and Biophysical Research Communications 2008 365 2 232 238 10.1016/j.bbrc.2007.10.162 2-s2.0-36248946819
281. Duan W., Peng Q., Masuda N., Ford E., Tryggestad E., Ladenheim B., Zhao M., Cadet J. L., Wong J., Ross C. A., Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiology of Disease 2008 30 3 312 322 10.1016/j.nbd.2008.01.015 2-s2.0-43649106471
282. Ju T.-C., Chen H.-M., Lin J.-T., Chang C.-P., Chang W.-C., Kang J.-J., Sun C.-P., Tao M.-H., Tu P.-H., Dickson D. W., Chern Y., Nuclear translocation of AMPK-&1 potentiates striatal neurodegeneration in Huntington's disease. The Journal of Cell Biology 2011 194 2 209 227 10.1083/jcb.201105010 2-s2.0-79961116788
283. Ruiz C., Casarejos M. J., Rubio I., Gines S., Puigdellivol M., Alberch J., Mena M. A., de Yebenes J. G., The dopaminergic stabilizer, (-)-OSU6162, rescues striatal neurons with normal and expanded polyglutamine chains in huntingtin protein from exposure to free radicals and mitochondrial toxins. Brain Research 2012 1459 100 112 10.1016/j.brainres.2012.04.021 2-s2.0-84861233461
284. Teles A. V. F., Rosenstock T. R., Okuno C. S., Lopes G. S., Bertoncini C. R., Smaili S. S., Increase in bax expression and apoptosis are associated in Huntington's disease progression. Neuroscience Letters 2008 438 1 59 63 10.1016/j.neulet.2008.03.062 2-s2.0-43549102381
285. Puigserver P., Wu Z., Park C. W., Graves R., Wright M., Spiegelman B. M., A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998 92 6 829 839 10.1016/S0092-8674(00)81410-5 2-s2.0-0032549811
286. Kelly D. P., Scarpulla R. C., Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes &; Development 2004 18 4 357 368 10.1101/gad.1177604 2-s2.0-1542373685
287. Handschin C., Spiegelman B. M., Peroxisome proliferator-activated receptor γ coactivator 1 coactivators, energy homeostasis, and metabolism. Endocrine Reviews 2006 27 7 728 735 10.1210/er.2006-0037 2-s2.0-33845596500
288. Cui L., Jeong H., Borovecki F., Parkhurst C. N., Tanese N., Krainc D., Transcriptional repression of PGC-1& by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006 127 1 59 69 10.1016/j.cell.2006.09.015 2-s2.0-33749042331
289. Weydt P., Pineda V. V., Torrence A. E., Libby R. T., Satterfield T. F., Lazarowski E., Gilbert M. L., Morton G. J., Bammler T. K., Strand A. D., Cui L., Beyer R. P., Easley C. N., Smith A. C., Krainc D., Luquet S., Sweet I., Schwartz M. W., La Spada A. R., Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1& in Huntington's disease neurodegeneration. Cell Metabolism 2006 4 5 349 362 10.1016/j.cmet.2006.10.004 2-s2.0-33750437278
290. Weydt P., Soyal S. M., Gellera C., Didonato S., Weidinger C., Oberkofler H., Landwehrmeyer G. B., Patsch W., The gene coding for PGC-1& modifies age at onset in Huntington's disease. Molecular Neurodegeneration 2009 4, article 3 10.1186/1750-1326-4-3 2-s2.0-58649094617
291. Johri A., Calingasan N. Y., Hennessey T. M., Sharma A., Yang L., Wille E., Chandra A., Beal M. F., Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. Human Molecular Genetics 2012 21 5 1124 1137 10.1093/hmg/ddr541 2-s2.0-84863011541
292. Chang D. T., Rintoul G. L., Pandipati S., Reynolds I. J., Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiology of Disease 2006 22 2 388 400 10.1016/j.envpol.2005.09.025 2-s2.0-33646136884
293. Orr A. L., Li S., Wang C.-E., Li H., Wang J., Rong J., Xu X., Mastroberardino P. G., Greenamyre J. T., Li X.-J., N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. The Journal of Neuroscience 2008 28 11 2783 2792 10.1523/JNEUROSCI.0106-08.2008 2-s2.0-40849147435
294. Costa V., Giacomello M., Hudec R., Lopreiato R., Ermak G., Lim D., Malorni W., Davies K. J. A., Carafoli E., Scorrano L., Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli. EMBO Molecular Medicine 2010 2 12 490 503 10.1002/emmm.201000102 2-s2.0-78650284389
295. Shirendeb U., Reddy A. P., Manczak M., Calkins M. J., Mao P., Tagle D. A., Reddy P. H., Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Human Molecular Genetics 2011 20 7 1438 1455 10.1093/hmg/ddr024 2-s2.0-79952585486